FOI Request
- Disclosure ID
- FOI/02378
- Request Date
- April 19, 2018
- Subject
- MabThera
- Description
- Do you have local clinical pathways or standard operating procedures (SOPs) for the use of MabThera? If so are you able to share these? For instance, is one cycle of MabThera intravenous (IV) always used before initiating the patients on MabThera subcutaneous (SC) in oncology indications?
- Number of patients treated* using MabThera subcutaneous versus MabThera intravenous in oncology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:*if number of patients treated is not available please provide information in units that you have available (e.g. vials, preparations…)
- Total number of patients treated* with MabThera (intravenous and subcutaneous) vs Rixathon vs Truxima in oncology and rheumatology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:*if number of patients treated is not available please provide information in units that you have available (e.g. vials, preparations…)
- Do you have local clinical pathways or standard operating procedures (SOPs) for the initiation of new patient treatment regimens? If so are you able to share these?
- Specifically, are new patients directly prescribed biosimilar rituximab (i.e. Truxima or Rixathon) instead of MabThera?
- Are existing patients being switched from MabThera intravenous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?
- Are any existing patients being switched from MabThera subcutaneous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?
- Number of patients treated* using rituximab biosimilars (Truxima and Rixathon) instead of MabThera (intravenous and subcutaneous) between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:*if number of patients treated is not available please provide information in units that you have available (e.g. vials, preparations…)
- As an organisation, are you aware of any financial savings made by using biosimilar rituximab (i.e. Truxima or Rixathon) vs MabThera between 2017-2018, if only partial data is available please indicate the timeframe the data refers to and the methods used to calculate the financial savings.
- Please provide information for the current contracts for Truxima, Rixathon, MabThera intravenous (IV) or subcutaneous (SC):*if the total contract value is not available, please provide the price range for each drug
- Related to question 10, if contracts are tiered by volume, could you please provide the thresholds for each tier and what is the price percentage difference between tiers?
- Response
PLEASE NOTE we are unable to split Haematology/Oncology data therefore HaemOnc and Rheumatology data supplied
- No, protocols refer to the drug (rituximab) rather than the brand (Mabthera) due to maintain accuracy across brands.
We use s/c mabthera in accordance with NHS England approved patients (ie maintenance lymphoma patients). Once they have completed IV rituximab through induction chemo. - :-
Oncology Financial Year Number of patients treated using MabThera Intravenous (if possible, please provide number of patients excluding those who were switched to MabThera subcutaneous)
Number of patients treated using MabThera Subcutaneous FY 2016-17 109 21 FY 2017-18 96 17 - :-
Financial Year Drug Number of patients treated in Oncology Number of patients treated in Rheumatology FY 2016-17 MabThera 130 34 Truxima 0 3 Rixathon FY 2017-18 MabThera 113 38 Truxima 55 3 Rixathon - Brand specific guidance comes from North West Coast Strategic Clinical Network
- Yes new patients are started on biosimilars but prescribed by brand
- Existing patients being treated with IV Mabthera will complete their course of treatment with the same brand of rituximab that they started on. They would not routinely be switched between cycles
- No
- :-
Financial Year Drug Oncology Rheumatology New patients treated directly with the biosimilar instead of MabThera Existing patients switched from MabThera to the biosimlar New patients treated directly with the biosimilar instead of MabThera Existing patients switched from MabThera to the biosimlar FY 2016-17 Truxima 0 0 0 0 Rixathon FY 2017-18 Truxima 40 unable to confirm start date 14 1 1 Rixathon - :-
Year Scheme (e.g. discounting, gainshare…) Approximate saving (£) NHSE funded as pass through costs - :-
Drug Contract value (£)* Volume of contract (number of vials) Is price tiered by volume? (Yes/No)
Length of contract Renewal frequency Services included Date of contract initiation Date of contract expiry Yes/No Which services (e.g. biosimilar education, patient support program…)
Rixathon Please see response below** Truxima As above MabThera IV As above MabThera SC As above ** Specific details relating to pricing and payment structure are confidential and commercially sensitive due to the nature of the agreements we have in place, therefore we are exempting this information under section 43(2) of the Freedom of Information Act 2000 as disclosure would prejudice the commercial interests of the Trust
- Specific details relating to pricing and payment structure are confidential and commercially sensitive due to the nature of the agreements we have in place, therefore we are exempting this information under section 43(2) of the Freedom of Information Act 2000 as disclosure would prejudice the commercial interests of the Trust
- No, protocols refer to the drug (rituximab) rather than the brand (Mabthera) due to maintain accuracy across brands.